Immunocompromised Host Vaccination

Immunocompromised host vaccination is the body of immunization principles that apply when a person's immune defences are weakened by disease, transplantation, or therapy. Two themes dominate: vaccine responses are often blunted, so protection may be reduced, and live attenuated vaccines are generally contraindicated because the weakened immune system may not control the replicating vaccine organism.

Definition

Immunocompromised host vaccination refers to immunization considerations in individuals with impaired immune function, characterized by potentially diminished vaccine responses and the general avoidance of live attenuated vaccines because of the risk that a weakened immune system cannot contain a replicating attenuated organism.

Scope

The topic covers the categories of immunocompromise (primary immunodeficiency, HIV, haematologic malignancy, transplantation, and immunosuppressive or biologic therapy), the reduced immunogenicity of vaccines in these hosts, the general avoidance of live vaccines, and the importance of timing -- vaccinating before planned immunosuppression where feasible. It treats these as reference principles drawn from guidelines, not as individualized clinical instructions.

Core questions

• Which conditions and therapies define an immunocompromised host for vaccination purposes?
• Why are live attenuated vaccines generally contraindicated in significant immunosuppression?
• How does the degree and type of immunosuppression affect expected vaccine response?
• Why does timing vaccination before planned immunosuppression matter?

Key concepts

• Live attenuated vaccine contraindication in significant immunosuppression
• Blunted humoral and cellular vaccine responses
• Pre-immunosuppression vaccination timing
• Inactivated and recombinant (non-live) vaccine preference
• Solid organ and haematopoietic stem cell transplant immunization
• Biologic and targeted therapy effects on vaccine response
• Cocooning of household and close contacts

Mechanisms

Vaccines elicit protection through antigen-driven activation of B and T lymphocytes; when these populations are depleted or functionally suppressed, the resulting antibody titres and memory responses are reduced, lowering and shortening protection. The same immune impairment removes the control that normally limits a live attenuated organism to subclinical replication, creating a risk of disseminated vaccine-strain infection -- the basis for the general contraindication to live vaccines in significant immunosuppression (rubin-2014; danziger-isakov-2019). Because impairment deepens after transplantation or once immunosuppressive and biologic therapies take effect, responses are typically better when vaccination precedes immunosuppression, and recombinant or inactivated platforms (such as the adjuvanted recombinant zoster vaccine) avoid the live-vaccine hazard altogether (lal-2015; redelman-sidi-2018).

Clinical relevance

Immunocompromised individuals carry elevated risk of severe vaccine-preventable infection, and the principles here explain why their immunization is approached differently. The entry is reference material describing those principles and the structure of relevant guidelines; it is not a source of individualized vaccination decisions, which depend on the specific condition, therapy, and timing.

Epidemiology

The immunocompromised population has expanded with wider use of transplantation and of immunosuppressive and biologic agents for autoimmune and inflammatory disease. These hosts experience higher rates of severe outcomes from influenza, invasive pneumococcal disease, and herpes zoster, which is the rationale for dedicated vaccination guidance (rubin-2014).

Evidence & guidelines

The 2013 IDSA guideline is the anchoring synthesis for vaccinating the immunocompromised host, complemented by American Society of Transplantation recommendations for transplant candidates and recipients and ESCMID consensus guidance on biologic and targeted therapies (rubin-2014; danziger-isakov-2019; redelman-sidi-2018). Trial evidence for non-live options in at-risk older and immunocompromised populations includes the adjuvanted recombinant zoster vaccine (lal-2015); comprehensive principles are summarised in standard vaccinology references (plotkin-2018).

History

As organ transplantation and immunosuppressive therapy expanded through the late twentieth century, the need for structured vaccination guidance in immunocompromised patients became apparent. The 2013 IDSA guideline consolidated decades of accumulated evidence into a single reference framework, and the subsequent arrival of recombinant, non-live vaccines such as the adjuvanted zoster subunit vaccine broadened the options available to these hosts (rubin-2014; lal-2015).

Debates

Can any live vaccines be given in milder immunosuppression?

Guidelines distinguish degrees of immunosuppression, and whether selected live vaccines may be acceptable in low-level or non-significant immunosuppression remains an area of careful, condition-specific judgement rather than a blanket rule.

Key figures

• Lorry Rubin
• Lara Danziger-Isakov
• Stanley Plotkin

Seminal works

• rubin-2014
• danziger-isakov-2019

Frequently asked questions

Why are live vaccines usually avoided in immunocompromised people?

Live attenuated vaccines contain weakened but replicating organisms; an impaired immune system may fail to control that replication, creating a risk of vaccine-strain disease, so live vaccines are generally contraindicated in significant immunosuppression.

Why is the timing of vaccination important before immunosuppression?

Vaccine responses are generally stronger when the immune system is more intact, so guidelines emphasise completing recommended immunizations before planned immunosuppression or transplantation where feasible.